FDA Lowers Sugar Rules for Pasteurized Orange Juice: OJ Shake-Up
Published Date: 8/6/2025
Proposed Rule
Summary
The FDA wants to change the rules for pasteurized orange juice by lowering the minimum sugar content from 10.5 to 10 degrees Brix. This update helps juice makers have more flexibility while keeping things honest for consumers. If approved, it’ll support Florida citrus groups and could shake up how your OJ is made soon.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Juice makers gain more flexibility
The FDA proposes lowering the minimum soluble solids for pasteurized orange juice from 10.5° Brix to 10° Brix. If finalized, this change would give juice manufacturers greater flexibility in how they make pasteurized orange juice and responds to a citizen petition from the Florida Citrus Processors Association Inc. and Florida Citrus Mutual Inc.
Consumers kept honest about orange juice
The FDA says lowering the minimum from 10.5° Brix to 10° Brix for pasteurized orange juice is intended to promote honesty and fair dealing in the interest of consumers. This proposed standard of identity change is meant to ensure labeling and product standards remain clear while allowing manufacturing flexibility.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-10321 — Vaccines and Related Biological Products Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Safety and Effectiveness of MFLUSIVA (Influenza Vaccine, mRNA) Manufactured by Moderna TX Inc.
The FDA is holding a public meeting on June 18, 2026, to talk about the safety and effectiveness of MFLUSIVA, a new flu vaccine made by Moderna. Anyone can watch online and share their thoughts before June 17. This is a big deal for people who get flu shots and could affect how this vaccine is used and approved.
2026-10295 — M11 Clinical Electronic Structured Harmonised Protocol (CeSHarP); International Council for Harmonisation; Guidance for Industry; Availability
The FDA just released a new, easy-to-use digital guide called M11 CeSHarP to help everyone involved in clinical trials share and review study plans faster and clearer. This affects drug companies, researchers, and regulators worldwide by setting a global standard for how trial info is written and shared electronically. The new rules kick in now, aiming to save time and reduce confusion, with no direct cost but big efficiency gains.
2026-10277 — Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability
The FDA just released new draft guides to help drug makers design studies proving their generic drugs work like the originals. If you’re in the drug business, now’s your chance to share feedback by July 21, 2026, before these guides become final. These updates aim to speed up drug approvals, potentially saving time and money for companies and patients alike!
2026-10284 — Protein Efficiency Ratio Rat Bioassay Studies To Demonstrate That a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein; Guidance for Industry; Availability
The FDA just released new guidance to help baby formula makers prove their products have good-quality protein using special rat studies. This update affects formula manufacturers and labs, making it easier and clearer to show their formulas meet nutrition standards. The guidance is effective now, helping companies avoid costly mistakes and speed up getting new formulas to market.
2026-10268 — Notice of Decision Not To Designate Hepatitis Delta Virus Diseases as an Addition to the Current List of Tropical Diseases in the Federal Food, Drug, and Cosmetic Act
The FDA decided not to add Hepatitis Delta Virus (HDV) to the list of tropical diseases because it doesn’t fully meet the rules about market size and who it affects. This means drug makers won’t get special priority review vouchers for HDV treatments right now. People working on HDV drugs should keep an eye out for future updates but won’t see changes or new incentives immediately.
2026-10190 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Patent Term Restoration; Due Diligence Petitions; Filing, Format, and Content of Petitions
The FDA is updating how companies ask for extra patent time when their new drugs or devices take a while to get approved. This affects drug and medical device makers who want to protect their inventions longer. Comments on these changes are open until June 22, 2026, and the update aims to keep the process clear without adding extra costs or delays.
Previous / Next Documents
Previous: 2025-14932 — Airworthiness Directives; Dassault Aviation Airplanes
If you fly a Dassault Falcon 7X, the FAA wants you to update your flight manual and equipment list to handle some tricky avionics problems. They’re also asking for a cool new fix to make your plane’s electronics stronger and safer. Some planes won’t need these updates anymore, but if yours does, expect to act soon and maybe spend a bit to keep flying safe and sound!
Next: 2025-14960 — Fisheries of the Exclusive Economic Zone Off Alaska; Amendment 125 to the Bering Sea and Aleutian Islands Fishery Management Plan; Pacific Cod Small Boat Access
This new rule helps small fishing boats (55 feet or less) catch Pacific cod in the Bering Sea and Aleutian Islands from January to April and count their catch toward the jig sector’s total. It gives small boat fishers more chances to join in and keeps the fishing game fair and steady. This change starts soon and supports sustainable fishing while opening doors for new fishers.